Creative Medical Technology Holdings, Inc. has begun expanding the scope of its Adapt clinical trial after receiving new approval from the US Food and Drug Administration (FDA).

Meanwhile, the company is rapidly advancing the Phase III clinical trial planning for its core candidate product Olastrocel for the treatment of chronic lower back pain. This regulatory progress has cleared obstacles for the expansion of the Adapt trial, marking a key step forward in the company's research in this therapeutic area. As a cell therapy targeting chronic pain, the subsequent development of Olastrocel has also been significantly accelerated. According to the company’s management, the rapid move towards Phase III trials is based on previously obtained positive data and ongoing feedback from the FDA. These actions highlight the company’s strategic determination to address the significant unmet medical need of chronic lower back pain.